Basic and clinical studies of gatifloxacin in the field of surgery

DOI 2 Citations 11 References

Bibliographic Information

Other Title
  • 外科領域におけるgatifloxacinの基礎的・臨床的検討

Search this article

Abstract

Basic and clinical studies of a new quinolone antimicrobial drug, gatifloxacin (GFLX, AM-1155), in the field of surgery were performed, with following results:<BR>1) A single dose of GFLX was orally administered to six patients in the amount of 150, 200, or 300 mg. Levels in serum reached a peak four hours after administration. GFLX levels in bile were higher than those in serum at all the times measured up to 24 hours, so biliary excretion seemed to be good.<BR>2) Clinical responses were excellent in 37 cases, good in 23 cases, fair in two cases, and poor in six cases, an efficacy rate of 88.2%. Bacteriological efficacy rate was 89.5%(51/57). Eradication rate for 129 strains identified was 90.0%(45/50) for gram-positive bacilli, 93.1%(27/29) for gram-negative bacilli, and 100%(50/50) for anaerobes, overall 94.6%(122/129). MIC90 of GFLX against clinical isolates were 3.13, μg/mL against 53 strains of gram-positive bacilli, 0.78 μg/mL against 28 strains of gram-negative bacilli, and 1.56 μg/mL against 51 strains of anaerobes. Against gram-positive bacilli and anaerobes, GFLX showed higher antibacterial activity than other quinolones tested.As for adverse reactions, a slight gastric discomfort was observed in one case. No abnormal changes were observed on clinical laboratory tests.<BR>In summary, GFLX seems to be a useful drug for the treatment of surgical infection.

Journal

Citations (2)*help

See more

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top